Left Ventricular Hypertrophy in Experimental Chronic Kidney Disease is Associated with Reduced Expression of Cardiac Kruppel-like Factor 15

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2018 Jul 5

PMID 29970016

Citations 4

Authors

Sheila K Patel

Elena Velkoska

Daniel Gayed

Jay Ramchand

Jessica Lesmana

Louise M Burrell

Affiliations

Soon will be listed here.

Abstract

Background: Left ventricular hypertrophy (LVH) increases the risk of death in chronic kidney disease (CKD). The transcription factor Kruppel-like factor 15 (KLF15) is expressed in the heart and regulates cardiac remodelling through inhibition of hypertrophy and fibrosis. It is unknown if KLF15 expression is changed in CKD induced LVH, or whether expression is modulated by blood pressure reduction using angiotensin converting enzyme (ACE) inhibition.

Methods: CKD was induced in Sprague-Dawley rats by subtotal nephrectomy (STNx), and rats received vehicle (n = 10) or ACE inhibition (ramipril, 1 mg/kg/day, n = 10) for 4 weeks. Control, sham-operated rats (n = 9) received vehicle. Cardiac structure and function and expression of KLF15 were assessed.

Results: STNx caused impaired kidney function (P < 0.001), hypertension (P < 0.01), LVH (P < 0.001) and fibrosis (P < 0.05). LVH was associated with increased gene expression of hypertrophic markers, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP, P < 0.01) and connective tissue growth factor (CTGF) (P < 0.05). Cardiac KLF15 mRNA and protein expression were reduced (P < 0.05) in STNx and levels of the transcription regulator, GATA binding protein 4 were increased (P < 0.05). Ramipril reduced blood pressure (P < 0.001), LVH (P < 0.001) and fibrosis (P < 0.05), and increased cardiac KLF15 gene (P < 0.05) and protein levels (P < 0.01). This was associated with reduced ANP, BNP and CTGF mRNA (all P < 0.05).

Conclusion: This is the first evidence that loss of cardiac KLF15 in CKD induced LVH is associated with unchecked trophic and fibrotic signalling, and that ACE inhibition ameliorates loss of cardiac KLF15.

Citing Articles

Sex-Specific Changes in Cardiac Function and Electrophysiology During Progression of Adenine-Induced Chronic Kidney Disease in Mice.

Dargam V, Sanchez A, Kolengaden A, Perez Y, Arias R, Valentin Cabrera A J Cardiovasc Dev Dis. 2024; 11(11).

PMID: 39590205 PMC: 11594452. DOI: 10.3390/jcdd11110362.

Intestinal microbiota by angiotensin receptor blocker therapy exerts protective effects against hypertensive damages.

Li J, Wang S, Yan K, Wang P, Jiao J, Wang Y Imeta. 2024; 3(4):e222.

PMID: 39135690 PMC: 11316932. DOI: 10.1002/imt2.222.

Study on the correlation between Left Ventricular Hypertrophy and Coronary Artery disease in the very elderly patients with hypertension.

Sun J, Liu X, Zhang Q, Zhang Q Pak J Med Sci. 2021; 37(5):1382-1386.

PMID: 34475916 PMC: 8377890. DOI: 10.12669/pjms.37.5.4135.

KLF15 Loss-of-Function Mutation Underlying Atrial Fibrillation as well as Ventricular Arrhythmias and Cardiomyopathy.

Li N, Xu Y, Shi H, Yang C, Guo Y, Li R Genes (Basel). 2021; 12(3).

PMID: 33809104 PMC: 8001991. DOI: 10.3390/genes12030408.

References

Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S . Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med. 2002; 8(8):856-63. DOI: 10.1038/nm738. View

Wang B, Haldar S, Lu Y, Ibrahim O, Fisch S, Gray S . The Kruppel-like factor KLF15 inhibits connective tissue growth factor (CTGF) expression in cardiac fibroblasts. J Mol Cell Cardiol. 2008; 45(2):193-7. PMC: 2566509. DOI: 10.1016/j.yjmcc.2008.05.005. View

Ruilope L, Schmieder R . Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008; 21(5):500-8. DOI: 10.1038/ajh.2008.16. View

Zheng Y, Kong Y, Li F . Krüppel-like transcription factor 11 (KLF11) overexpression inhibits cardiac hypertrophy and fibrosis in mice. Biochem Biophys Res Commun. 2013; 443(2):683-8. DOI: 10.1016/j.bbrc.2013.12.024. View

Leenders J, Wijnen W, Hiller M, van der Made I, Lentink V, van Leeuwen R . Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem. 2010; 285(35):27449-27456. PMC: 2930743. DOI: 10.1074/jbc.M110.107292. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Rajamannan N, Subramaniam M, Abraham T, Vasile V, Ackerman M, Monroe D . TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway. J Cell Biochem. 2006; 100(2):315-25. PMC: 3927779. DOI: 10.1002/jcb.21049. View

Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C . Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2008; 74(11):1461-7. DOI: 10.1038/ki.2008.484. View

Devereux R, Roman M, De Simone G, OGrady M, Paranicas M, Yeh J . Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation. 1997; 96(5):1416-23. DOI: 10.1161/01.cir.96.5.1416. View

10.

Green D, Roberts P, New D, Kalra P . Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis. 2011; 57(6):921-9. DOI: 10.1053/j.ajkd.2011.02.376. View

11.

Charytan D . Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Curr Opin Nephrol Hypertens. 2014; 23(6):578-85. PMC: 4266593. DOI: 10.1097/MNH.0000000000000067. View

12.

Haldar S, Ibrahim O, Jain M . Kruppel-like Factors (KLFs) in muscle biology. J Mol Cell Cardiol. 2007; 43(1):1-10. PMC: 2743293. DOI: 10.1016/j.yjmcc.2007.04.005. View

13.

Haldar S, Lu Y, Jeyaraj D, Kawanami D, Cui Y, Eapen S . Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation. Sci Transl Med. 2010; 2(26):26ra26. PMC: 3003709. DOI: 10.1126/scitranslmed.3000502. View

14.

Candido R, Forbes J, Thomas M, Thallas V, Dean R, Burns W . A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003; 92(7):785-92. DOI: 10.1161/01.RES.0000065620.39919.20. View

15.

Burchill L, Velkoska E, Dean R, Lew R, Smith A, Levidiotis V . Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol. 2008; 93(5):622-30. DOI: 10.1113/expphysiol.2007.040386. View

16.

Liang Q, de Windt L, Witt S, Kimball T, Markham B, Molkentin J . The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem. 2001; 276(32):30245-53. DOI: 10.1074/jbc.M102174200. View

17.

Velkoska E, Patel S, Griggs K, Burrell L . Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. PLoS One. 2016; 11(8):e0161760. PMC: 5003360. DOI: 10.1371/journal.pone.0161760. View

18.

Liao X, Haldar S, Lu Y, Jeyaraj D, Paruchuri K, Nahori M . Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J Mol Cell Cardiol. 2010; 49(2):334-8. PMC: 2885477. DOI: 10.1016/j.yjmcc.2010.04.008. View

19.

Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H . Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res. 2006; 29(4):253-60. DOI: 10.1291/hypres.29.253. View

20.

Fisch S, Gray S, Heymans S, Haldar S, Wang B, Pfister O . Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2007; 104(17):7074-9. PMC: 1855421. DOI: 10.1073/pnas.0701981104. View